Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurizio Rocchetti

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumorsRoger B Cohen, Suzanne F Jones, Charu Aggarwal, et al.
Molecular Cancer Therapeutics|December 20, 2007
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancerPatrizia Carpinelli, Roberta Ceruti, Maria Laura Giorgini, et al.
Neuromuscular Disorders : NMD|August 28, 2016
Histological effects of givinostat in boys with Duchenne muscular dystrophyPaolo Bettica, Stefania Petrini, Valentina D'Oria, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2009
Modelling the genesis and treatment of cancer: the potential role of physiologically based pharmacodynamicsJean-Louis Steimer, Svein G Dahl, Dinesh P De Alwis, et al.
Molecular Cancer Therapeutics|February 10, 2012
NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignanciesBarbara Valsasina, Italo Beria, Cristina Alli, et al.
Journal of Medicinal Chemistry|November 28, 2006
1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profileDaniele Fancelli, Jürgen Moll, Mario Varasi, et al.
Journal of Medicinal Chemistry|April 20, 2010
Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitorsItalo Beria, Dario Ballinari, Jay Aaron Bertrand, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumorsRoger B Cohen, Suzanne F Jones, Charu Aggarwal, et al.
Molecular Cancer Therapeutics|December 20, 2007
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancerPatrizia Carpinelli, Roberta Ceruti, Maria Laura Giorgini, et al.
Neuromuscular Disorders : NMD|August 28, 2016
Histological effects of givinostat in boys with Duchenne muscular dystrophyPaolo Bettica, Stefania Petrini, Valentina D'Oria, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2009
Modelling the genesis and treatment of cancer: the potential role of physiologically based pharmacodynamicsJean-Louis Steimer, Svein G Dahl, Dinesh P De Alwis, et al.
Molecular Cancer Therapeutics|February 10, 2012
NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignanciesBarbara Valsasina, Italo Beria, Cristina Alli, et al.
Journal of Medicinal Chemistry|November 28, 2006
1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profileDaniele Fancelli, Jürgen Moll, Mario Varasi, et al.
Journal of Medicinal Chemistry|April 20, 2010
Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitorsItalo Beria, Dario Ballinari, Jay Aaron Bertrand, et al.
Pageof 3